Table 1.

Intra-individual stability of an eGFR decline ≥ 30% over time.

	eGFR decline ≥ 30% from baseline until
	1st year of FU	2nd year of FU	3rd year of FU	4th year of FU	5th year of FU
PROVALID (n = 860)
FU1 (n/%)	25 (100)	6 (24.0)	4 (16.0)	4 (16.0)	4 (16.0)
FU2 (n/%)	6 (10.9)	55 (100)	29 (52.7)	20 (36.4)	16 (29.1)
FU3 (n/%)	8 (11.0)	29 (39.7)	73 (100)	44 (60.3)	33 (45.2)
FU4 (n/%)	15 (16.0)	26 (27.7)	44 (46.8)	94 (100)	53 (56.4)
FU5 (n/%)	14 (12.0)	32 (27.4)	44 (37.6)	53 (45.3)	117 (100)
Validation cohort (n = 178)
FU1 (n/%)	5 (100)	4 (80.0)	2 (40.0)	2 (40.0)	2 (40.0)
FU2 (n/%)	4 (36.4)	11 (100)	5 (45.5)	4 (36.4)	4 (36.4)
FU3 (n/%)	2 (33.3)	5 (83.3)	6 (100)	4 (66.7)	4 (66.7)
FU4 (n/%)	4 (20.0)	5 (25.0)	4 (20.0)	20 (100)	13 (65.0)
FU5 (n/%)	4 (16.0)	7 (28.0)	6 (24.0)	13 (52.0)	25 (100)

FU follow up.

The tables should be read as follows: The vertical lines indicate the number and percentage of patients meeting a specific definition of eGFR decline over time. For example, 25 individuals of the PROVALID cohort had a decrease of eGFR ≥ 30% after one year of follow-up and form the cohort that is followed (100%). Of these, only 6 meet also meet the definition of eGFR decline after 2 years of follow-up (24%) (these numbers are given in bold letters). In the next line, we used a definition of a decline in eGFR ≥ 30% during the first 2 years of follow-up and identified 55 individuals (again forming 100% of the population). Of these, only 6 (10.9%) already have lost more than 30% of baseline eGFR after one year, whereas 26 individuals recovered renal function during the third year of follow-up, leaving only 29 (52.7%) individuals persistently meeting the definition of eGFR decline. When looking at the diagonal reading, one can see that on a cohort level the number of patients with a loss of eGFR ≥ 30% is increasing from 25 to 117 over time.